Therefore, while an HNSCC patient is considered a Cluster 1 subtype or is assessed with a low CRRS, immunotherapy mainly focused on PD-1/CTLA-4 blockade may result in a better prognosis. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.